By IPOMarket Editorial Team · Last reviewed: May 20, 2026
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
The Bio Medica Laboratories IPO 2026 opens on May 21, 2026 and closes on May 25, 2026 at a price band of ₹132-139 per share, raising ₹52.43 crore through a fresh issue plus a small offer-for-sale (3.77 lakh shares) on the NSE SME platform. The Indore-based parenteral formulations manufacturer brings to market 58 liquid injectable products and 15 dry powder injectable products across human and veterinary applications — a niche, regulated category with structural growth tailwinds.
This review covers the IPO mechanics, business model, financial scale, GMP trajectory and a decision framework for prospective applicants. For broader pipeline context, see our open IPOs page and the live IPO GMP page.
Bio Medica Laboratories IPO — Key Details at a Glance
| Parameter | Details |
|---|---|
| Open Date | May 21, 2026 |
| Close Date | May 25, 2026 |
| Allotment Date | May 26, 2026 |
| Listing Date | May 29, 2026 |
| Price Band | ₹132 – ₹139 per share |
| Issue Size | ₹52.43 Cr (Fresh Issue + OFS 3.77 lakh shares) |
| Lot Size | 1,000 shares |
| Min Investment (Retail) | ₹2,78,000 (2,000 shares) |
| Exchange | NSE SME |
| Lead Manager | Narnolia Financial Services |
| Registrar | Skyline Financial Services |
| GMP Today | Live IPO GMP → |
| Allotment Status | Check allotment → |
About Bio Medica Laboratories
Bio Medica Laboratories is an Indore-based pharmaceutical company specialising in parenteral formulations — sterile injectable medicines for both human and veterinary use. Founded in August 2015, the company has built a focused portfolio of:
- 58 liquid injectable products — sterile aqueous and oily solutions for IV/IM administration.
- 15 dry powder injectable products — lyophilised or reconstituted-on-use formulations for active pharmaceutical ingredients with limited liquid stability.
- Human and veterinary applications — dual-end-market revenue diversification.
The company operates a B2B contract manufacturing model, supplying branded pharma marketers, distributors and exporters. As of March 2026, the company employs 362 full-time employees and 223 contract staff, reflecting the labour intensity of sterile injectable manufacturing.
Key operational and quality credentials include GMP and GLP certifications along with international technical collaborations that underpin the export-readiness of the manufacturing facility. The injectable formulations category in India is a structural growth segment — both for domestic generic supply and for export to regulated/semi-regulated markets across Africa, ASEAN and Latin America.
Financial Performance
Detailed financials will be confirmed in the RHP; the company's growth trajectory across FY24-FY26 has reflected:
- Capacity additions. Both liquid injectable and dry powder injectable lines have seen capacity scale-up.
- Product portfolio expansion. 58 + 15 SKUs is a meaningful catalogue for an SME-stage injectable manufacturer.
- Veterinary segment growth. Veterinary pharma has been a higher-growth, less price-pressured segment than human generics.
For category context on Indian pharma IPOs, see our introduction to IPOs.
GMP and Market Sentiment
As of the days leading up to the issue opening, no active grey market premium was being quoted for Bio Medica Laboratories. The absence of GMP is not unusual for niche, low-profile SME pharma issues — it reflects limited grey-market participation rather than a negative signal per se.
Investors should track the GMP daily on the live IPO GMP page as the subscription window progresses; early GMP often appears once Day 1 and Day 2 subscription momentum builds.
Strengths
- Niche, regulated category. Sterile injectable manufacturing has high entry barriers — GMP certification, capital intensity, and regulatory compliance create a structural moat.
- Dual end-market. Human + veterinary pharma diversification smooths revenue cyclicality.
- GMP/GLP certified. Critical for both domestic credibility and any export-market expansion.
- International technical collaborations. Indicate technology partnerships that elevate manufacturing quality.
- Diverse product portfolio. 58 + 15 SKUs provide revenue diversification across therapeutic categories.
Risks and Concerns
- Concentration in injectables. While a strength category-wise, concentration in a single dosage form creates regulatory event-risk — any USFDA-style observation on the facility (for export-ready manufacturers) materially impacts revenue.
- Regulatory risk. Injectable manufacturing is the most regulated pharma dosage form — any inspection observation, recall, or quality event has outsized financial impact.
- B2B client concentration. Contract manufacturing typically concentrates revenue across a small number of marketing partners.
- No active GMP yet. Limited pre-IPO sentiment indicator for investors looking for grey-market signals.
- SME platform liquidity. NSE SME stocks see materially lower daily volume than mainboard.
Should You Apply?
The decision framework for Bio Medica rests on three balancing factors:
- For. Niche injectable category with high entry barriers, GMP/GLP credentials, international collaborations, and a diverse product portfolio.
- Against. No active GMP, single-dosage-form concentration risk, and regulatory event-risk inherent to injectable manufacturing.
- Neutral. B2B contract manufacturing concentration is typical of the category — not unique to Bio Medica.
For investors with appetite for SME pharma exposure and a multi-year horizon, the underlying category positioning supports a measured application at minimum lot size. Track Day 1 and Day 2 subscription on the live SME IPO subscription page before committing larger allocations. For investors who want broader IPO context, see the upcoming IPOs in 2026 list and the Bio Medica Laboratories IPO profile.
Key Dates
| Event | Date |
|---|---|
| Open Date | May 21, 2026 |
| Close Date | May 25, 2026 |
| Allotment Finalization | May 26, 2026 |
| Refunds Initiated | May 27, 2026 |
| Shares Credited to Demat | May 28, 2026 |
| Listing Date | May 29, 2026 |
Frequently Asked Questions
What is the Bio Medica Laboratories IPO price band? The price band is ₹132 to ₹139 per share with a lot size of 1,000 shares and a minimum retail investment of ₹2,78,000 (2,000 shares).
When is the Bio Medica Laboratories IPO listing date? The shares are expected to list on NSE SME on May 29, 2026, following allotment on May 26, 2026.
What is the Bio Medica Laboratories IPO GMP today? No active GMP was being quoted in the days leading up to the issue opening. Check the live IPO GMP page for the latest trajectory.
What does Bio Medica Laboratories do? Bio Medica is an Indore-based parenteral formulations manufacturer — sterile injectable medicines (58 liquid injectables and 15 dry powder injectables) for human and veterinary applications.
How can I check Bio Medica Laboratories IPO allotment status? Use our IPO allotment status checker or the registrar (Skyline Financial Services) portal. PAN-based lookup gives instant status.
This article is for informational purposes only and does not constitute investment advice. Please read the RHP carefully before investing.